SCHEDULE: White Lion Capital Discloses 5% Stake in Akari Therapeutics

White Lion Capital LLC has reported beneficial ownership of 5.0% of Akari Therapeutics Plc's ordinary shares, represented by American Depositary Shares, as of August 7, 2026.

Summary

• White Lion Capital LLC has filed a Schedule 13G, reporting beneficial ownership of 7,001,638,477 ordinary shares of Akari Therapeutics Plc.
• This stake represents 5.0% of the total outstanding ordinary shares.
• The shares are represented by American Depositary Shares (ADS), with each ADS representing 80,000 ordinary shares.
• The ownership is a result of potential issuances under an equity line Common Stock Purchase Agreement.
• The filing date is August 7, 2026, and the percentage is based on 140,032,769,533 ordinary shares outstanding as of June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not overwhelming ownership stake by a financial entity, with no immediate negative implications.

Positives

• White Lion Capital LLC has taken a significant ownership position, potentially signaling confidence in Akari Therapeutics' future prospects.
• The ownership is structured through an equity line agreement, suggesting a flexible and potentially ongoing relationship.
• The filing is a standard Schedule 13G, indicating compliance with regulatory requirements for significant shareholders.

Negatives

• The filing does not provide details on the specific terms or conditions of the equity line Common Stock Purchase Agreement.
• The large number of shares held by a single entity could lead to concentrated selling pressure if they decide to divest.

Risks

• The potential for future share issuances under the equity line agreement could dilute existing shareholders if not managed effectively.
• The concentration of ownership could lead to increased volatility if White Lion Capital LLC decides to significantly alter its position.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Akari Therapeutics. The future outlook is indirectly influenced by the potential for future share issuances under the equity line agreement.

Management Comments

• White Lion Capital LLC certifies that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms like White Lion Capital are common in the biotechnology and pharmaceutical sectors, often indicating a belief in the company's pipeline or market potential. This filing places Akari Therapeutics within the typical landscape of companies attracting institutional investment.

Stakeholder Impact

• Shareholders: Potential for dilution if shares are issued under the equity line agreement; potential for increased share price volatility due to concentrated ownership.
• Creditors: No immediate impact indicated, but significant capital raises could alter the company's debt-to-equity ratio.
• Employees: Indirect impact through company stability and potential growth fueled by capital raises.

Next Steps

• Monitoring future disclosures from White Lion Capital LLC regarding any changes in their ownership stake.
• Observing Akari Therapeutics' utilization of the equity line Common Stock Purchase Agreement for potential capital raises.

Key Dates

Recommendation

The filing indicates a significant ownership stake by White Lion Capital, which could be interpreted as a sign of confidence, but it also highlights a potential for future dilution through an equity line agreement. Without further operational or financial updates from Akari Therapeutics, the current information warrants a 'hold' position to observe how this ownership stake and potential capital raises unfold.

Keywords

Akari Therapeutics, White Lion Capital, Schedule 13G, Beneficial Ownership, American Depositary Shares, Equity Line Agreement, Shareholder